A Phase 2 Proof-of-Concept Study to Evaluate the Effects of NDX-1017 to Treat Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs NDX 1017 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Athira Pharma
- 11 Apr 2019 According to a M3 Biotechnology media release, this study is planned to start in 2019.
- 11 Apr 2019 According to a M3 Biotechnology media release, the companys phase 2 trials including this trial will be supported in part by the Alzheimer's Association through its PART THE CLOUD to RESCUE Program.
- 11 Apr 2019 According to a M3 Biotechnology media release, the company has changed its name from M3 Biotechnology to Athira Pharma, Inc.